DE69524679D1 - Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure - Google Patents

Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure

Info

Publication number
DE69524679D1
DE69524679D1 DE69524679T DE69524679T DE69524679D1 DE 69524679 D1 DE69524679 D1 DE 69524679D1 DE 69524679 T DE69524679 T DE 69524679T DE 69524679 T DE69524679 T DE 69524679T DE 69524679 D1 DE69524679 D1 DE 69524679D1
Authority
DE
Germany
Prior art keywords
combination
bowing
medicament
mycophenolic acid
possibly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69524679T
Other languages
English (en)
Other versions
DE69524679T2 (de
Inventor
Randall Ellis Morris
Clare Robert Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69524679(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of DE69524679D1 publication Critical patent/DE69524679D1/de
Application granted granted Critical
Publication of DE69524679T2 publication Critical patent/DE69524679T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69524679T 1994-05-12 1995-05-10 Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure Expired - Lifetime DE69524679T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/238,305 US5516781A (en) 1992-01-09 1994-05-12 Method of treating restenosis with rapamycin

Publications (2)

Publication Number Publication Date
DE69524679D1 true DE69524679D1 (de) 2002-01-31
DE69524679T2 DE69524679T2 (de) 2002-06-13

Family

ID=22897329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69524679T Expired - Lifetime DE69524679T2 (de) 1994-05-12 1995-05-10 Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure

Country Status (15)

Country Link
US (4) US5516781A (de)
EP (1) EP0691130B1 (de)
JP (2) JP4514838B2 (de)
KR (1) KR100446026B1 (de)
AT (1) ATE210979T1 (de)
AU (1) AU706486B2 (de)
CA (1) CA2148871C (de)
CY (1) CY2332B1 (de)
DE (1) DE69524679T2 (de)
DK (1) DK0691130T3 (de)
ES (1) ES2166802T3 (de)
HK (1) HK1010333A1 (de)
NZ (1) NZ272092A (de)
PT (1) PT691130E (de)
SI (1) SI0691130T1 (de)

Families Citing this family (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69435185D1 (de) 1993-07-19 2009-03-05 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CA2219659C (en) 1995-06-09 2008-03-18 Novartis Ag Rapamycin derivatives
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6624138B1 (en) 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
US20050163818A1 (en) * 1996-11-05 2005-07-28 Hsing-Wen Sung Drug-eluting device chemically treated with genipin
US7282220B1 (en) 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
US7351421B2 (en) * 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US8790391B2 (en) * 1997-04-18 2014-07-29 Cordis Corporation Methods and devices for delivering therapeutic agents to target vessels
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20070087028A1 (en) * 1998-04-16 2007-04-19 Robert Falotico Intraluminal devices for the prevention and treatment of vascular disease
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
EP1980263A1 (de) * 1999-05-10 2008-10-15 Novartis AG Kombinationen von immunsuppressiven Mitteln zur Behandlung bzw. Prävention von Transplantatabstoßungen
AU4941400A (en) * 1999-05-27 2001-01-22 Biocompatibles Limited Local drug delivery
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6899731B2 (en) * 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
JP2003528114A (ja) * 2000-03-24 2003-09-24 マイクロメット アーゲー インターフェロンγシグナル伝達経路のモジュレータの同定および再狭窄治療におけるそれらの使用
JPWO2001076587A1 (ja) * 2000-04-06 2004-01-08 小野薬品工業株式会社 狭窄性血管病変に基づく疾患治療剤
ES2233650T3 (es) * 2000-05-03 2005-06-16 Fidia Advanced Biopolymers S.R.L. Biomateriales formados por celulas preadipocito para reparacion de tejidos blandos.
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) * 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
EP1709974A3 (de) * 2000-06-16 2006-12-06 Wyeth Verfahren zur behandlung von kardiovaskulären erkrankungen mit rapamycin
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US6506408B1 (en) * 2000-07-13 2003-01-14 Scimed Life Systems, Inc. Implantable or insertable therapeutic agent delivery device
MXPA03002258A (es) 2000-09-19 2003-06-24 Wyeth Corp Esteres de rapamicina solubles en agua.
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6923927B2 (en) * 2000-10-03 2005-08-02 Atrium Medical Corporation Method for forming expandable polymers having drugs or agents included therewith
EP2103284B1 (de) * 2000-10-16 2016-12-21 Conor Medsystems, Inc. Expandierbare medizinische Vorrichtung zur Freisetzung eines Heilmittels
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US8192484B2 (en) 2000-12-12 2012-06-05 Cardiatis S.A. Stent for blood flow improvement
CA2429352A1 (en) * 2000-12-15 2002-06-20 Lieven Stuyver Antiviral agents for treatment of flaviviridae infections
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
AU2002249958B2 (en) 2001-01-16 2007-11-08 Vascular Therapies, Inc. Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US8182527B2 (en) * 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
US6818013B2 (en) 2001-06-14 2004-11-16 Cordis Corporation Intravascular stent device
US6673106B2 (en) 2001-06-14 2004-01-06 Cordis Neurovascular, Inc. Intravascular stent device
JP2005508671A (ja) * 2001-07-26 2005-04-07 アバンテク バスキュラー コーポレーション 治療に有効な薬剤の送達
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
JP2005501868A (ja) 2001-08-22 2005-01-20 ワイス ラパマイシン２９−エノール
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
WO2003035135A1 (en) * 2001-09-24 2003-05-01 Boston Scientific Limited Optimized dosing for drug coated stents
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1465624A1 (de) * 2002-01-10 2004-10-13 Novartis AG Therapeutische systeme zur prophylaxe und behandlung von gefässerkrankungen welche rapamycin oder derivate hiervon enthalten
US20040068314A1 (en) * 2002-01-16 2004-04-08 Jones Donald K. Detachable self -expanding aneurysm cover device
IL162734A0 (en) * 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
WO2003083105A1 (fr) * 2002-03-28 2003-10-09 Medicalseed Co., Ltd. Traitement et prevention de l'angiostenose
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7754238B2 (en) * 2002-05-03 2010-07-13 Avi Biopharma, Inc. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
US20030208166A1 (en) * 2002-05-06 2003-11-06 Schwartz Anthony H. Implantable device with free-flowing exit and uses thereof
WO2003094904A1 (en) * 2002-05-13 2003-11-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
US7195648B2 (en) 2002-05-16 2007-03-27 Cordis Neurovascular, Inc. Intravascular stent device
WO2003099169A1 (en) 2002-05-20 2003-12-04 Orbus Medical Technologies Inc. Drug eluting implantable medical device
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
US6833003B2 (en) * 2002-06-24 2004-12-21 Cordis Neurovascular Expandable stent and delivery system
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US20050019404A1 (en) * 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
US20060171984A1 (en) * 2002-09-06 2006-08-03 Cromack Keith R Device having hydration inhibitor
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
US7001422B2 (en) * 2002-09-23 2006-02-21 Cordis Neurovascular, Inc Expandable stent and delivery system
US7976936B2 (en) * 2002-10-11 2011-07-12 University Of Connecticut Endoprostheses
WO2004043509A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
WO2004073768A2 (en) * 2003-02-18 2004-09-02 Medtronic, Inc. Occlusion resistant hydrocephalic shunt
US20090093875A1 (en) 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
WO2004087045A2 (en) * 2003-03-28 2004-10-14 Kosan Biosciences, Inc. Devices, methods, and compositions to prevent restenosis
EP1610823B1 (de) 2003-03-28 2011-09-28 Innovational Holdings, LLC Implantierbares medizinprodukt mit kontinuierlichem mittel-konzentrationsgefälle
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
AU2004231720A1 (en) * 2003-04-22 2004-11-04 Wyeth Antineoplastic combinations
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20040236410A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Polymeric body formation
US20040236278A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Therapeutic agent delivery
US20040236279A1 (en) * 2003-05-22 2004-11-25 Atrium Medical Corp. Gaseous therapeutic agent delivery
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US7226473B2 (en) * 2003-05-23 2007-06-05 Brar Balbir S Treatment of stenotic regions
EP1628787A4 (de) * 2003-05-30 2007-04-25 Chief Automotive Technologies Mehrere bewegliche schlitten mit bahnen mit mehreren radien und geneigten rollen
US20060240014A1 (en) * 2003-06-03 2006-10-26 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
US20040253185A1 (en) * 2003-06-12 2004-12-16 Atrium Medical Corp. Medicated ink
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050049668A1 (en) * 2003-08-29 2005-03-03 Jones Donald K. Self-expanding stent and stent delivery system for treatment of vascular stenosis
US20050049669A1 (en) 2003-08-29 2005-03-03 Jones Donald K. Self-expanding stent and stent delivery system with distal protection
US20050049670A1 (en) * 2003-08-29 2005-03-03 Jones Donald K. Self-expanding stent and stent delivery system for treatment of vascular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7244441B2 (en) * 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US20050171596A1 (en) * 2004-02-03 2005-08-04 Furst Joseph G. Stents with amphiphilic copolymer coatings
US8097269B2 (en) * 2004-02-18 2012-01-17 Celonova Biosciences, Inc. Bioactive material delivery systems comprising sol-gel compositions
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
WO2005082277A1 (en) * 2004-02-18 2005-09-09 Stanford University Drug delivery systems using mesoporous oxide films
ES2315745T3 (es) * 2004-03-01 2009-04-01 Terumo Kabushiki Kaisha Procedimiento para la fabricacion de derivados o-alquilados de rapamicina.
JP5755395B2 (ja) 2004-03-10 2015-07-29 オーバスネイチ メディカル、インコーポレイテッド 薬剤溶出式の植設可能な医療デバイスによる前駆内皮細胞の捕捉方法
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
ATE534424T1 (de) * 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050251152A1 (en) * 2004-05-05 2005-11-10 Atrium Medical Corp. Illuminated medicated ink marker
US20050261639A1 (en) * 2004-05-05 2005-11-24 Atrium Medical Corp. Medicated ink marker
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US8236338B2 (en) * 2004-07-13 2012-08-07 The University Of Tennessee Research Foundation Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2006036912A2 (en) * 2004-09-27 2006-04-06 Echobio Llc Systems, apparatus and methods related to helical, non-helical or removable stents with rectilinear ends
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
JP5335244B2 (ja) * 2005-03-03 2013-11-06 アイコン メディカル コーポレーション 改良された金属合金を用いた医療用部材
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20090216317A1 (en) * 2005-03-23 2009-08-27 Cromack Keith R Delivery of Highly Lipophilic Agents Via Medical Devices
US20070250148A1 (en) * 2005-09-26 2007-10-25 Perry Kenneth E Jr Systems, apparatus and methods related to helical, non-helical or removable stents with rectilinear ends
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US7914573B2 (en) * 2005-12-13 2011-03-29 Cordis Corporation Polymeric stent having modified molecular structures
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
US20070212386A1 (en) * 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Coatings for implantable medical devices
DK2001466T3 (en) * 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US8690935B2 (en) 2006-04-28 2014-04-08 DePuy Synthes Products, LLC Stent delivery system with threaded engagement and method
US7655031B2 (en) * 2006-04-28 2010-02-02 Codman & Shurtleff, Inc. Stent delivery system with improved retraction member
US8118859B2 (en) * 2006-05-26 2012-02-21 Codman & Shurtleff, Inc. Occlusion device combination of stent and mesh having offset parallelogram porosity
EP2020956A2 (de) 2006-05-26 2009-02-11 Nanyang Technological University Implantierbarer artikel, verfahren zu seiner herstellung sowie verfahren zur verminderung von thrombogenität
US8690938B2 (en) * 2006-05-26 2014-04-08 DePuy Synthes Products, LLC Occlusion device combination of stent and mesh with diamond-shaped porosity
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
CN104906087A (zh) 2006-09-13 2015-09-16 万能医药公司 大环内酯化合物及它们的使用方法
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
EP2114479A2 (de) * 2006-10-27 2009-11-11 Medtronic, Inc. Angiotensin (1-7) freisetzender stent
AU2007319825B2 (en) * 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090043330A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Embolic protection devices and methods
US20090043380A1 (en) * 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
JP2011500150A (ja) * 2007-10-10 2011-01-06 エムアイヴィ テラピューティクス， インコーポレイテッド インプラント用医療デバイスのための脂質コーティング
US20090112239A1 (en) * 2007-10-31 2009-04-30 Specialized Vascular Technologies, Inc. Sticky dilatation balloon and methods of using
US8573150B2 (en) 2007-11-14 2013-11-05 Biosensors International Group, Ltd. Automated stent coating apparatus and method
CA2711765A1 (en) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US9114125B2 (en) 2008-04-11 2015-08-25 Celonova Biosciences, Inc. Drug eluting expandable devices
US8206635B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US8206636B2 (en) 2008-06-20 2012-06-26 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US10898620B2 (en) 2008-06-20 2021-01-26 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof
US8765162B2 (en) * 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
US20100047319A1 (en) * 2008-08-21 2010-02-25 Michael Huy Ngo Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
WO2010040064A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
ES2440751T3 (es) * 2008-10-07 2014-01-30 Boston Scientific Scimed, Inc. Dispositivos médicos para administración de agentes terapéuticos a los lúmenes corporales
WO2010054121A2 (en) * 2008-11-07 2010-05-14 Specialized Vascular Technologies, Inc. Extracellular matrix modulating coatings for medical devices
EP2416792A4 (de) 2009-04-10 2012-10-24 Haiyan Qi Neue anti-aging-mittel und verfahren zu ihrer identifizierung
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
CA3186201A1 (en) * 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
US8628790B2 (en) 2009-10-09 2014-01-14 Pls Technologies, Llc Coating system and method for drug elution management
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
US9220759B2 (en) 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
NZ701992A (en) 2012-05-14 2016-03-31 Bard Inc C R Uniformly expandable stent
WO2014070792A1 (en) 2012-10-29 2014-05-08 Ariste Medical, Inc. Polymer coating compositions and coated products
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
USD723165S1 (en) 2013-03-12 2015-02-24 C. R. Bard, Inc. Stent
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
CN106471074A (zh) 2014-04-22 2017-03-01 阿里斯特医疗公司 用于施加药物递送聚合物涂料的方法和工艺
WO2015199816A1 (en) 2014-06-24 2015-12-30 Icon Medical Corp. Improved metal alloys for medical devices
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
CN114057818B (zh) * 2021-10-08 2023-10-17 重庆大学 抑制损伤血管内膜增生的纳米药物及其应用
WO2023200951A1 (en) * 2022-04-14 2023-10-19 James Biggins Methods, devices and systems for treating neointimal growth

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators

Also Published As

Publication number Publication date
EP0691130B1 (de) 2001-12-19
KR100446026B1 (ko) 2004-12-23
KR950031066A (ko) 1995-12-18
CY2332B1 (en) 2004-02-06
CA2148871A1 (en) 1995-11-13
NZ272092A (en) 1997-07-27
DK0691130T3 (da) 2002-03-11
SI0691130T1 (en) 2002-04-30
EP0691130A1 (de) 1996-01-10
AU706486B2 (en) 1999-06-17
AU1791895A (en) 1995-11-23
US5665728A (en) 1997-09-09
US5646160A (en) 1997-07-08
ES2166802T3 (es) 2002-05-01
ATE210979T1 (de) 2002-01-15
JP4514838B2 (ja) 2010-07-28
DE69524679T2 (de) 2002-06-13
CA2148871C (en) 2009-09-15
US5563146A (en) 1996-10-08
JP2007277269A (ja) 2007-10-25
PT691130E (pt) 2002-06-28
JPH0840901A (ja) 1996-02-13
HK1010333A1 (en) 1999-06-17
US5516781A (en) 1996-05-14

Similar Documents

Publication Publication Date Title
DE69524679T2 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE69328981D1 (de) Verfahren zur Behandlung von hyperproliferaktiven Gefässerkrankungen unter Verwendung von Rapamycin, eventuell in Kombination mit Mykophenolsäure
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE122005000005I2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE69433713D1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
DE69218255T2 (de) Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
DE3855525T2 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
DE69031168T2 (de) Verwendung von IGF1 oder IGF2 zur Herstellung eines Medikaments für die Behandlung von amyotrophischen Lateralsklerose
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
DE69925488D1 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
ATE249832T1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69431320D1 (de) Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
ATE98127T1 (de) Verwendung von peroxidlipiden zur herstellung eines arzneimittels zur behandlung von kreislaufinsuffizienz bei lokaler applikation.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J.

8364 No opposition during term of opposition